文献速递神经MR

大鼠和人类静脉注射钆基对比剂后大脑皮质内钆的不均匀滞留

Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans.
PubMed 文献 · Radiology · 2019-11-26

研究在大鼠和人类大脑中探究钆是否滞留于大脑皮质及具体位置。钆喷酸葡胺处理的大鼠新皮质内钆滞留呈区域、亚区和分层特异性,且滞留钆与实质铁共定位,但未见T1加权MRI信号增强。两例反复暴露钆基对比剂的人类供体大脑皮质、软脑膜及软脑膜血管内检出钆滞留,而两例未暴露者未检出。

要点

  • 钆喷酸葡胺处理大鼠新皮质内钆滞留呈区域、亚区和分层特异性。
  • 滞留钆与实质铁共定位,但未观察到T1加权MRI信号增强。
  • 两例反复暴露钆基对比剂的人类大脑皮质、软脑膜及软脑膜血管内检出钆滞留,两例未暴露者未检出。

核心结论

  • 反复暴露钆喷酸葡胺与大脑皮质特定区域、亚区和分层内钆滞留相关,这些区域对高级认知、情感和行为调节、感觉运动协调及执行功能至关重要。

研究设计与样本

  • 动物实验联合人类供体脑组织分析;Sprague-Dawley大鼠接受钆喷酸葡胺(4周内三次给药,累积钆剂量7.2 mmol/kg体重,n=6)或生理盐水(n=6),行生前MRI检查。

关键影像表现/征象

  • 钆喷酸葡胺处理大鼠新皮质内钆滞留呈区域、亚区和分层特异性,前扣带皮质平均钆浓度0.28 µg·g⁻¹ ± 0.04(均值标准误)。
  • 新皮质钆滞留与异皮质(梨状皮质0.33 µg·g⁻¹ ± 0.04,齿状回0.24 µg·g⁻¹ ± 0.04,海马0.17 µg·g⁻¹ ± 0.04)及皮质下结构(面神经核0.47 µg·g⁻¹ ± 0.10,脉络丛0.39 µg·g⁻¹ ± 0.10,尾状壳核0.29 µg·g⁻¹ ± 0.05,丘脑网状核0.26 µg·g⁻¹ ± 0.05,前庭核0.24 µg·g⁻¹ ± 0.04)相比差异无统计学意义(P > .05)。
  • 新皮质钆滞留显著高于小脑(0.17 µg·g⁻¹ ± 0.03,P = .01)和白质束(前连合0.05 µg·g⁻¹ ± 0.01,P = .002;胼胝体0.05 µg·g⁻¹ ± 0.02,P = .001;脑神经0.02 µg·g⁻¹ ± 0.01,P = .004)。
  • 滞留钆与实质铁共定位,但未观察到T1加权MRI信号增强。
  • 两例反复暴露钆基对比剂的人类供体大脑(分别给药三次和15次,暴露后1个月和5个月)中,在大脑皮质、软脑膜及软脑膜血管内检出钆滞留;两例未暴露钆基对比剂的人类供体大脑未检出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Gadolinium retention after repeated gadolinium-based contrast agent (GBCA) exposure has been reported in subcortical gray matter. However, gadolinium retention in the cerebral cortex has not been systematically investigated. Purpose To determine whether and where gadolinium is retained in rat and human cerebral cortex. Materials and Methods The cerebral cortex in Sprague-Dawley rats treated with gadopentetate dimeglumine (three doses over 4 weeks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; n = 6) or saline (n = 6) was examined with antemortem MRI. Two human donors with repeated GBCA exposure (three and 15 doses; 1 and 5 months after exposure), including gadopentetate dimeglumine, and two GBCA-naive donors were also evaluated. Elemental brain maps (gadolinium, phosphorus, zinc, copper, iron) for rat and human brains were constructed by using laser ablation inductively coupled plasma mass spectrometry. Results Gadopentetate dimeglumine-treated rats showed region-, subregion-, and layer-specific gadolinium retention in the neocortex (anterior cingulate cortex: mean gadolinium concentration, 0.28 µg ∙ g-1 ± 0.04 [standard error of the mean]) that was comparable (P > .05) to retention in the allocortex (mean gadolinium concentration, 0.33 µg ∙ g-1 ± 0.04 in piriform cortex, 0.24 µg ∙ g-1 ± 0.04 in dentate gyrus, 0.17 µg ∙ g-1 ± 0.04 in hippocampus) and subcortical structures (0.47 µg ∙ g-1 ± 0.10 in facial nucleus, 0.39 µg ∙ g-1 ± 0.10 in choroid plexus, 0.29 µg ∙ g-1 ± 0.05 in caudate-putamen, 0.26 µg ∙ g-1 ± 0.05 in reticular nucleus of the thalamus, 0.24 µg ∙ g-1 ± 0.04 in vestibular nucleus) and significantly greater than that in the cerebellum (0.17 µg ∙ g-1 ± 0.03, P = .01) and white matter tracts (anterior commissure: 0.05 µg ∙ g-1 ± 0.01, P = .002; corpus callosum: 0.05 µg ∙ g-1 ± 0.02, P = .001; cranial nerve: 0.02 µg ∙ g-1 ± 0.01, P = .004). Retained gadolinium colocalized with parenchymal iron. T1-weighted MRI signal intensification was not observed. Gadolinium retention was detected in the cerebral cortex, pia mater, and pia-ensheathed leptomeningeal vessels in two GBCA-exposed human brains but not in two GBCA-naive human brains. Conclusion Repeated gadopentetate dimeglumine exposure is associated with gadolinium retention in specific regions, subregions, and layers of cerebral cortex that are critical for higher cognition, affect, and behavior regulation, sensorimotor coordination, and executive function. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Kanal in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Minaeva O, Hua N, Franz ES, et al. Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans. Radiology. 2019. PMID: 31769744. doi:10.1148/radiol.2019190461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。